Response to Imatinib therapy is inferior for e13a2 <i>BCR-ABL1</i> transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia.

BMC Hematol · 2019 · PMC6498698 · PMID 31073408

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

marginally outside the level of significancep = 0.05actually significant

The results were similar for achieving MR 4.5 with BCR-ABL1 < 0.0032% however, the difference between the two groups was marginally outside the level of significance for time to achievement ( p = 0.05).

also in 0 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.